Mirvie Appoints Fertility Veteran David Stern to Scale RNA Diagnostics

SOUTH SAN FRANCISCO, Calif. – November 10, 2026 — The transition from a promising clinical-stage biotechnology startup to a commercial juggernaut requires a distinct shift in corporate DNA. Today, that evolutionary leap was on full display in the maternal health sector. Slone Partners, a premier executive search firm specializing in life sciences, announced the placement of healthcare veteran David Stern as the new Chief Executive Officer of Mirvie. He succeeds the company’s co-founder, Maneesh Jain, PhD, who will transition to the role of Executive Vice Chair of the Board.

This executive reshuffle is far more than a routine C-suite update; it is a clear signal that the nascent precision obstetrics market is entering its commercialization phase. The San Francisco-based biotech firm has spent years building its proprietary RNA platform, a technology designed to detect the biological risks of pregnancy complications months before clinical symptoms appear. Now, with a scientifically validated product and a CLIA-certified laboratory in place, the mandate has shifted from research and development to aggressive market access, payer negotiation, and clinical adoption.

"Maternal health is at an inflection point, and Mirvie is positioned to lead it," said Leslie Loveless, CEO and Managing Partner at Slone Partners, who spearheaded the executive search. "David pairs three decades of women's health leadership with hands-on experience building commercial businesses, from product launch through a successful acquisition."

From R&D to Commercial Scale: The Classic Biotech Pivot

The changing of the guard at the top of the startup reflects a classic inflection point in the life sciences playbook. Scientific founders like Jain are instrumental in translating abstract biological concepts into viable clinical tools. Under his tenure, the enterprise published landmark peer-reviewed evidence—including a pivotal 2021 study in Nature Medicine that demonstrated how analyzing tens of thousands of RNA messages could accurately predict spontaneous preterm birth. The firm also successfully established a CLIA-certified and CAP-accredited laboratory, creating the necessary infrastructure to process its complex molecular assays as Laboratory Developed Tests (LDTs).

"Founding and leading Mirvie has been the work of a lifetime, and I am delighted to pass the torch to David to accelerate and scale our commercial growth," Jain noted in the announcement. "The Board and I are excited to partner with David as we work to change the trajectory of preterm birth and maternal health outcomes, which remain unacceptably poor for too many expectant mothers in America."

However, the skills required to sequence RNA and publish in top-tier medical journals are fundamentally different from those needed to secure national reimbursement contracts or convince entrenched hospital systems to adopt new diagnostic protocols. Enter David Stern.

Stern brings a formidable resume of commercial execution in the women’s health space. Industry observers closely watched his tenure at Symbiomix Therapeutics, where he navigated the arduous FDA approval process for Solosec, a breakthrough single-dose treatment for bacterial vaginosis. More importantly for investors, he steered that company to a lucrative $150 million acquisition by Lupin Pharmaceuticals in 2017. That specific track record—taking a novel therapeutic from the regulatory gauntlet through a successful commercial exit—is exactly what venture backers like BlackRock, Khosla Ventures, and General Catalyst are banking on for their latest investment.

The Femtech Consolidation Era: Exporting the Fertility Playbook

Stern’s appointment also highlights a fascinating migration of executive talent and venture capital within the broader "Femtech" ecosystem. For the past decade, the lion’s share of innovation and funding in women's health has been heavily concentrated in the fertility and family-building sectors.

Stern himself is a product of this environment. Prior to joining the RNA diagnostics startup, he served as CEO of Kindbody, a rapidly expanding national fertility clinic network and family-building benefits provider. Before that, he was the chief executive of Boston IVF, one of the largest fertility center networks in the United States. In both roles, he mastered the art of scaling clinical operations, optimizing patient acquisition costs, and negotiating with massive employer health plans.

Now, the market is signaling that the fertility playbook is ready to be exported to mainstream obstetrics. The maternal health space has historically suffered from underinvestment and a reliance on outdated, generalized clinical guidelines. By bringing a seasoned fertility executive into the prenatal diagnostic fold, the industry is acknowledging that precision maternal care is ripe for the same commercial transformation that revolutionized in vitro fertilization.

"Pregnancy is one of the last outdated frontiers of medicine that is still managed largely by one-size-fits-all guidelines," Stern stated regarding his new role. "What Maneesh and the team have built is rare: molecular insight into the biology of each pregnancy, a clinically validated test, established payer coverage, and growing demand from clinicians and patients. I've watched precision tools transform outcomes and the patient experience in fertility care, and I believe the technologies we are pioneering at Mirvie can do the same for pregnancy."

Beyond One-Size-Fits-All: The RNA Frontier in Obstetrics

The fundamental premise of the new CEO's mission is that molecular diagnostics can fundamentally alter the tragic trajectory of America’s maternal health crisis. The United States currently holds the highest maternal mortality rate among developed nations, with severe complications impacting one in five pregnancies. Conditions like preeclampsia and spontaneous preterm birth are notoriously difficult to predict using traditional demographic risk factors or standard ultrasound imaging.

By analyzing the dynamic transcriptomic landscape—specifically, the cell-free RNA shed by the mother, the fetus, and the placenta into the maternal bloodstream—the technology aims to provide a highly personalized risk profile. This moves prenatal care from a reactive posture to a proactive one. If a clinician knows a patient is at an elevated molecular risk for preeclampsia at week 16, they can implement closer monitoring protocols or prophylactic treatments like low-dose aspirin well before blood pressure spikes dangerously.

However, the company is not operating in a vacuum. The competitive landscape for maternal biomarkers is intensifying. Competitors like Sera Prognostics have already made headway with protein-based blood tests like the PreTRM test, while genetic testing giants like Natera and emerging players like Ravgen are continuously exploring the boundaries of non-invasive prenatal testing (NIPT) and cell-free DNA/RNA analysis.

To outmaneuver these rivals, the incoming executive will need to leverage the unique comprehensive nature of the platform. Rather than looking for a single isolated biomarker, the technology’s ability to analyze a vast array of RNA messages offers a more holistic, systems-level view of placental and maternal health. Translating that scientific complexity into a simple, actionable, and reimbursable clinical tool will be the defining challenge of his tenure.

Navigating the Payer Labyrinth

The most immediate hurdle facing the new leadership is the notoriously complex U.S. reimbursement landscape. While the firm has touted early successes in establishing payer coverage, achieving the kind of ubiquitous national reimbursement required to truly scale operations is a grueling, multi-year process.

In the diagnostic space, commercial success is inextricably linked to clinical guidelines. To unlock broad coverage from the Centers for Medicare & Medicaid Services (CMS) and major commercial health plans, the RNA platform will ultimately need to be integrated into the clinical recommendations of influential bodies like the American College of Obstetricians and Gynecologists (ACOG). Securing this endorsement requires not just proof of predictive accuracy, but robust health economics data demonstrating that early detection actually leads to improved clinical outcomes and reduced downstream healthcare costs.

The cost of a premature birth to the U.S. healthcare system is staggering, often running into the hundreds of thousands of dollars per infant in neonatal intensive care unit (NICU) expenses. If the new administration can successfully articulate and prove the cost-saving potential of proactive RNA screening, the value proposition for payers becomes undeniable.

As the firm transitions from its early scientific innings to this critical commercial phase, the broader healthcare sector will be watching closely. The successful integration of precision molecular diagnostics into routine prenatal care could serve as a blueprint for modernizing obstetrics, finally replacing blunt demographic risk assessments with targeted, data-driven interventions that safeguard the lives of mothers and their children.